Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_federal_law
|
| gptkbp:administeredBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:amendedBy |
gptkb:Food_and_Drug_Administration_Modernization_Act_of_1997
|
| gptkbp:appliesTo |
drugs for diseases affecting fewer than 200,000 people in the US
|
| gptkbp:codifiedIn |
gptkb:21_U.S.C._§_360bb_et_seq.
|
| gptkbp:created |
gptkb:Orphan_Products_Board
|
| gptkbp:dateEnacted |
January 4, 1983
|
| gptkbp:effect |
increased number of orphan drugs approved
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| https://www.w3.org/2000/01/rdf-schema#label |
Orphan Drug Act of 1983
|
| gptkbp:nickname |
gptkb:ODA
|
| gptkbp:provides |
grants for clinical testing
market exclusivity for orphan drugs tax credits for clinical research |
| gptkbp:purpose |
encourage development of drugs for rare diseases
|
| gptkbp:relatedTo |
pharmaceutical industry
rare diseases |
| gptkbp:signedBy |
gptkb:Ronald_Reagan
|
| gptkbp:bfsParent |
gptkb:Federal_Food,_Drug,_and_Cosmetic_Act
|
| gptkbp:bfsLayer |
6
|